AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27864127 — intervention group
Group type: EXPERIMENTAL
Intervention: latiglutenase 100, 300, 450, 600, or 900 mg daily for 12 or 24 weeks
Number of subjects: 494
Study 27864127 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 494
Study 24983679 — intervention group
Group type: EXPERIMENTAL
Intervention: Doula support
Number of subjects: 214
Study 24983679 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 214
Study 23347994 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable power (VAR) cycling at 65% MAP
Number of subjects: 12
Study 23347994 — intervention group
Group type: COMPARATOR
Intervention: Constant power (CON) cycling at 65% MAP
Number of subjects: 12
Study 23347994 — intervention group
Group type: COMPARATOR
Intervention: Control 9.3‐km run with no preceding exercise
Number of subjects: 12
Study 21280267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine with water
Number of subjects: 14
Study 21280267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine with apple juice
Number of subjects: 14
Study 21280267 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam with apple juice
Number of subjects: 14
Study 21280267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine uptake by OATP2B1 cRNA‐injected oocytes
Number of subjects: 14
Study 21280267 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple juice effect on fexofenadine uptake
Number of subjects: 14
Study 19853699 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control with heart rate >=80 beat/min
Number of subjects: 522
Study 19853699 — intervention group
Group type: COMPARATOR
Intervention: Rate control with heart rate <80 beat/min
Number of subjects: 522
Study 16503582 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface lidocaine anesthesia
Number of subjects: 34
Study 16503582 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger pressure probes (1.6 and 15 mm)
Number of subjects: 34
Study 12467956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose solution swallowed (0, 5, 10, 20, and 40%)
Number of subjects: 60
Study 12467956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose solution spit (0, 5, 10, 20, and 40%)
Number of subjects: 60
Study 12467956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear to swallow sucrose solution (covariate)
Number of subjects: 60
Study 12467956 — intervention group
Group type: EXPERIMENTAL
Intervention: Drive for Thinness (covariate)
Number of subjects: 60
Study 12467956 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Anhedonia
Number of subjects: 60
Study 12467956 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Anhedonia
Number of subjects: 60
Study 10635540 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO beverage (Drink 1)
Number of subjects: 16
Study 10635540 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 16
Study 10635540 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO beverage (Drink 2)
Number of subjects: 16
Study 10635540 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available drinks (Drink 3)
Number of subjects: 16
Study 10635540 — intervention group
Group type: EXPERIMENTAL
Intervention: Water (Drink 4)
Number of subjects: 16
Study 10635540 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available drinks (Drink 5)
Number of subjects: 16
Study 10635540 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO beverage
Number of subjects: 16
Study 11327791 — intervention group
Group type: EXPERIMENTAL
Intervention: Posteroanterior central vertebral pressure (PA mobilisation)
Number of subjects: 18
Study 2206140 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplements
Number of subjects: 0
Study 2206140 — intervention group
Group type: COMPARATOR
Intervention: Alpha‐tocopherol‐enriched coconut oil supplements (placebo)
Number of subjects: 0
Study 7227621 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothiaden (75 mg)
Number of subjects: 50
Study 7227621 — intervention group
Group type: COMPARATOR
Intervention: Lentizol (50 mg)
Number of subjects: 50
Study 30385886 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counseling and testing among White/Other YBCS
Number of subjects: 883
Study 30385886 — intervention group
Group type: COMPARATOR
Intervention: Barriers to access genetic services
Number of subjects: 883
Study 30385886 — intervention group
Group type: COMPARATOR
Intervention: Factors negatively associated with use of genetic services
Number of subjects: 883
Study 30385886 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of breast cancer risk factors
Number of subjects: 883
Study 30385886 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education and genetic counseling
Number of subjects: 883
Study 29314065 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) with open-flap debridement (OFD)
Number of subjects: 90
Study 29314065 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF + porous hydroxyapatite (HA) with OFD
Number of subjects: 90
Study 29314065 — intervention group
Group type: COMPARATOR
Intervention: Control group (OFD alone)
Number of subjects: 90
Study 29314065 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) with OFD
Number of subjects: 90
Study 25953494 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock wave therapy (ESWT)
Number of subjects: 60
Study 25953494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical composed of alpha lipoic acid (ALA), conjugated linoleic acid (GLA), and Echinacea angustifolia
Number of subjects: 60
Study 23433822 — intervention group
Group type: EXPERIMENTAL
Intervention: Prize-based abstinence incentive intervention
Number of subjects: 415
Study 23433822 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 415
Study 20833820 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-improvement intervention targeting clinicians with five components: clinician education, local champions, academic detailing, clinician feedback of quality data, and system supports.
Number of subjects: 2318
Study 19812443 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-GalCer 0.1 microg/kg
Number of subjects: 26
Study 19812443 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-GalCer 1 microg/kg
Number of subjects: 26
Study 19812443 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-GalCer 10 microg/kg
Number of subjects: 26
Study 19812443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 16802067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT) with a belly board
Number of subjects: 20
Study 16802067 — intervention group
Group type: COMPARATOR
Intervention: Intensity-modulated radiotherapy (IMRT) without a belly board
Number of subjects: 20
Study 16081625 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 30
Study 16081625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12237187 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 12237187 — intervention group
Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 0
Study 10075098 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 7
Study 7553070 — intervention group
Group type: EXPERIMENTAL
Intervention: injections of allergen-specific antibody complexes
Number of subjects: 19
Study 2187982 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus relaxation and breathing therapy (Treatment A)
Number of subjects: 156
Study 2187982 — intervention group
Group type: COMPARATOR
Intervention: Exercise training only (Treatment B)
Number of subjects: 156
Study 7315768 — intervention group
Group type: EXPERIMENTAL
Intervention: Repletion diet (depletion diet plus 200 micrograms Se/day as high-Se wheat or wheat plus tuna fish)
Number of subjects: 6
Study 7315768 — intervention group
Group type: COMPARATOR
Intervention: Depletion diet (33 to 36 micrograms Se/day)
Number of subjects: 6
Study 31498113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after one-month dual antiplatelet therapy (DAPT)
Number of subjects: 0
Study 31498113 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT followed by 12-month aspirin monotherapy (control)
Number of subjects: 0
Study 31071483 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal retraining
Number of subjects: 84
Study 31071483 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (care-as-usual)
Number of subjects: 84
Study 28322366 — intervention group
Group type: EXPERIMENTAL
Intervention: Xyliwhite toothpaste (xylitol)
Number of subjects: 48
Study 28322366 — intervention group
Group type: EXPERIMENTAL
Intervention: Periobiotic toothpaste (xylitol-probiotic)
Number of subjects: 48
Study 28322366 — intervention group
Group type: COMPARATOR
Intervention: Colgate Max Fresh toothpaste (fluoride)
Number of subjects: 48
Study 27583931 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anesthesia (Group A)
Number of subjects: 80
Study 27583931 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anesthesia with hypertension (Group B)
Number of subjects: 80
Study 27583931 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (Group C)
Number of subjects: 80
Study 27583931 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with hypertension (Group D)
Number of subjects: 80
Study 23823329 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-Exercise Group
Number of subjects: 107
Study 23823329 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Group
Number of subjects: 107
Study 23823329 — intervention group
Group type: COMPARATOR
Intervention: Exercise Group
Number of subjects: 107
Study 23823329 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 107
Study 23225838 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (100 mg, 3 times a day for 60 days) + Botulinum toxin A (local intramuscular injections)
Number of subjects: 58
Study 23225838 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin A (local intramuscular injections only)
Number of subjects: 58
Study 23225838 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine + Botulinum toxin A
Number of subjects: 58
Study 23225838 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin A
Number of subjects: 58
Study 19229454 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise video programme (n=10), advised to follow 4 times a week for 6 weeks
Number of subjects: 20
Study 19229454 — intervention group
Group type: COMPARATOR
Intervention: Chronic obstructive pulmonary disease educational booklet only (n=10)
Number of subjects: 20
Study 17449945 — intervention group
Group type: EXPERIMENTAL
Intervention: Coflex (Spine motion, Germany)
Number of subjects: 42
Study 17449945 — intervention group
Group type: COMPARATOR
Intervention: PLIF
Number of subjects: 42
Study 15023158 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative plasma viral load measurements
Number of subjects: 364
Study 15023158 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine monitoring of CMV plasma viral load
Number of subjects: 364
Study 15023158 — intervention group
Group type: EXPERIMENTAL
Intervention: Single time point measures at the end of prophylaxis or month 4
Number of subjects: 364
Study 12185405 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg mirtazapine
Number of subjects: 6
Study 12185405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9832077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lycopene supplementation (tomato juice, spaghetti sauce, tomato oleoresin) for 1 week each
Number of subjects: 19
Study 9832077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary lycopene supplementation
Number of subjects: 19
Study 9832077 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 19
Study 7857508 — intervention group
Group type: EXPERIMENTAL
Intervention: hypericum extract
Number of subjects: 24
Study 7857508 — intervention group
Group type: COMPARATOR
Intervention: maprotiline
Number of subjects: 24
Study 2562333 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (10 mg or 20 mg each morning for 2 weeks)
Number of subjects: 9
Study 2562333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily for 2 weeks)
Number of subjects: 9
Study 2562333 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg nightly for 1 year)
Number of subjects: 9
Study 1179368 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC and vincristine (VCR) in 3 day courses repeated every 4‐5 weeks
Number of subjects: 42
Study 1179368 — intervention group
Group type: COMPARATOR
Intervention: DTIC, VCR and chloroethyl cyclohexyl nitrosourea in 3 day courses repeated every 6‐7 weeks
Number of subjects: 42
Study 1179368 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with chemotherapy
Number of subjects: 42
Study 29858027 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg/day)
Number of subjects: 147
Study 29858027 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2) and Bevacizumab (7.5 mg/kg) every 21 days
Number of subjects: 147
Study 29858027 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 147
Study 29858027 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel-bevacizumab
Number of subjects: 147
Study 27250219 — intervention group
Group type: EXPERIMENTAL
Intervention: Beauty care program (two training sessions per month for 3 months and daily facial skin care)
Number of subjects: 871
Study 27250219 — intervention group
Group type: COMPARATOR
Intervention: Control group (comprehensive geriatric assessment)
Number of subjects: 871
Study 24184299 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplement for eight weeks
Number of subjects: 70
Study 24184299 — intervention group
Group type: COMPARATOR
Intervention: Placebo for eight weeks
Number of subjects: 70
Study 21452176 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (40 mg/day)
Number of subjects: 49
Study 21452176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 49
Study 21452176 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 49
Study 20170345 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic endometrioma stripping surgery
Number of subjects: 47
Study 20170345 — intervention group
Group type: COMPARATOR
Intervention: Normo-ovulatory control cases
Number of subjects: 47
Study 18520184 — intervention group
Group type: EXPERIMENTAL
Intervention: Endolymphatic sac drainage and steroid instillation (G-I)
Number of subjects: 197
Study 18520184 — intervention group
Group type: EXPERIMENTAL
Intervention: Endolymphatic sac drainage without steroid instillation (G-II)
Number of subjects: 197
Study 18520184 — intervention group
Group type: COMPARATOR
Intervention: No treatment (G-III)
Number of subjects: 197
Study 15921829 — intervention group
Group type: EXPERIMENTAL
Intervention: MC-4 vaccine
Number of subjects: 100
Study 12570111 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 750
Study 10725767 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplement (200 mg DHA/day)
Number of subjects: 10
Study 10725767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10725767 — intervention group
Group type: COMPARATOR
Intervention: (13)C-labeled linoleic acid (1 mg/kg body weight)
Number of subjects: 10
Study 8542857 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine-adrenaline before starting surgery and a booster dose after 60 min
Number of subjects: 20
Study 8542857 — intervention group
Group type: COMPARATOR
Intervention: Epidural dose of bupivacaine-adrenaline at 60 min
Number of subjects: 20
Study 1781803 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 500 mg with glycine 250 mg
Number of subjects: 20
Study 1781803 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 500 mg without glycine
Number of subjects: 20
Study 6168829 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol (0.1, 0.25, and 0.5 mg)
Number of subjects: 0
Study 6168829 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol (10 times higher dose after beta-blockers)
Number of subjects: 0
Study 6168829 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (10 mg)
Number of subjects: 0
Study 6168829 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (20 mg)
Number of subjects: 0
Study 30159664 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 180
Study 30159664 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed message
Number of subjects: 180
Study 30159664 — intervention group
Group type: EXPERIMENTAL
Intervention: Message elaboration
Number of subjects: 180
Study 27125661 — intervention group
Group type: EXPERIMENTAL
Intervention: Social condition (e-cigarette ads focused on social enhancement)
Number of subjects: 187
Study 27125661 — intervention group
Group type: EXPERIMENTAL
Intervention: Health condition (e-cigarette ads focused on harm-reduction)
Number of subjects: 187
Study 27125661 — intervention group
Group type: EXPERIMENTAL
Intervention: Social condition
Number of subjects: 187
Study 27125661 — intervention group
Group type: COMPARATOR
Intervention: Control condition (ads of everyday objects only)
Number of subjects: 187
Study 23544435 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h exposure to second-hand smoke (SHS)
Number of subjects: 19
Study 23544435 — intervention group
Group type: COMPARATOR
Intervention: Normal room air (control)
Number of subjects: 19
Study 22192847 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-H5N1 vaccine
Number of subjects: 3647
Study 20210562 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump therapy (SAPT)
Number of subjects: 495
Study 20210562 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 495
Study 18984887 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week buprenorphine-naloxone (up to 24 mg per day for 9 weeks, then tapered to week 12)
Number of subjects: 152
Study 18984887 — intervention group
Group type: COMPARATOR
Intervention: Detox group (14-day taper, up to 14 mg per day)
Number of subjects: 152
Study 18984887 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week buprenorphine-naloxone
Number of subjects: 152
Study 18984887 — intervention group
Group type: COMPARATOR
Intervention: Detox group
Number of subjects: 152
Study 15974485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 352
Study 15974485 — intervention group
Group type: EXPERIMENTAL
Intervention: Gui‐zhi‐fu‐ling‐wan (herbal therapy)
Number of subjects: 352
Study 15974485 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without hot flashes)
Number of subjects: 352
Study 12098350 — intervention group
Group type: EXPERIMENTAL
Intervention: Case conferencing initiated by specialist services and arranged flexibly
Number of subjects: 29
Study 12098350 — intervention group
Group type: COMPARATOR
Intervention: Traditional case conferencing
Number of subjects: 29
Study 11029568 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine-clonidine (75 microg clonidine combined with 0.125% bupivacaine)
Number of subjects: 41
Study 11029568 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine-fentanyl (50 microg fentanyl combined with 0.125% bupivacaine)
Number of subjects: 41
Study 11029568 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine-fentanyl
Number of subjects: 41
Study 11029568 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine-clonidine
Number of subjects: 41
Study 9170302 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual case description (raters informed of actual abuse status)
Number of subjects: 40
Study 9170302 — intervention group
Group type: COMPARATOR
Intervention: Pretend case description (raters informed of opposite abuse status)
Number of subjects: 40
Study 1550043 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% fat diet with 9% saturated fatty acids (Step 1 diet)
Number of subjects: 48
Study 1550043 — intervention group
Group type: COMPARATOR
Intervention: Average American diet (AAD)
Number of subjects: 48
Study 1550043 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% fat diet with 14% saturated fatty acids (Sat diet)
Number of subjects: 48
Study 3699241 — intervention group
Group type: EXPERIMENTAL
Intervention: Varidase
Number of subjects: 38
Study 3699241 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 38
Study 30150280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) and intravitreal fasudil (IVF)
Number of subjects: 44
Study 30150280 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 44
Study 30182732 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (broad spectrum vitamins, minerals, and amino acids)
Number of subjects: 0
Study 30182732 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27307358 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (IV administration of 15 mg/kg of TXA combined with topical administration of 1 g/100 mL of TXA)
Number of subjects: 150
Study 27307358 — intervention group
Group type: EXPERIMENTAL
Intervention: Single IV group (IV administration of 15 mg/kg of TXA)
Number of subjects: 150
Study 27307358 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 150
Study 25609368 — intervention group
Group type: EXPERIMENTAL
Intervention: Real needle acupuncture
Number of subjects: 19
Study 25609368 — intervention group
Group type: COMPARATOR
Intervention: Park sham needle acupuncture
Number of subjects: 19
Study 25609368 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (16 participants)
Number of subjects: 19
Study 23761133 — intervention group
Group type: EXPERIMENTAL
Intervention: ASIST training (n = 31)
Number of subjects: 55
Study 23761133 — intervention group
Group type: COMPARATOR
Intervention: Resilience Retreat (control, n = 24)
Number of subjects: 55
Study 20605942 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent follow‐in comments
Number of subjects: 32
Study 20605942 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent follow‐in directives
Number of subjects: 32